On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

Published On: 6/21/2021

Duration: 11 minutes, 55 seconds

Related Article: "Viloxazine (Qelbree): A Faster Strattera?", The Carlat Child Psychiatry Report, April/May/June 2021

Resources:

• 
  
• Nasser A et al, Clin Ther 2020;42(8):1452–1466
  
• Johnson JK et al, J Atten Disord 2020;24(2):348-358
  
• Faraone SV, P T. 2009;34(12):678-683, 694.
  
• de Silva V et al, BMC Psychiatry 2011;11:176.
  

Got Feedback? Take the podcast survey.